Central Europe: Key Trends In The Drive For Pharmaceutical AusterityNovember 2011 | Industry Trend Analysis
BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients and drug companies. Austerity measures have been a key factor in lower growth recorded in 2010 and 2011. While 2012 is set to be an unusually difficult year for drugmakers in Central Europe, as an array of legislated measures across the region take force, we maintain our view that the longer-term (post-2012) growth potential of this region is favourable, particularly compared to the stagnant and limited growth expected in Western Europe.
To read the full article, please choose one of the following options: